Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
QIAGEN and Lilly collaborate to support development of a QIAstat-Dx IVD panel that identifies patients at risk for developing Alzheimer’s disease
Thursday, September 05, 2024QIAGEN announced it has entered into a collaboration with Eli Lilly and Company to support the development of a QIAstatDx invitro diagnostic IVD to detect APOE genotypes which can play a role in the diagnosis of Alzheimers disease This collaboration
ADVANZ PHARMA secures temporary suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe
Thursday, September 05, 2024ADVANZ PHARMA Holdco Limited a UK headquartered pharmaceutical company today announces that the General Court of the European Union General Court has temporarily suspended the European Commission EC decision to revoke the conditional
Actimed Therapeutics Announces US FDA Grant of Orphan Drug Designation to S-oxprenolol (ACM-002) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Wednesday, September 04, 2024Actimed Therapeutics Ltd a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders announces that the US Food
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
Wednesday, September 04, 2024Ascendis Pharma AS and Royalty Pharma plc today announced that Ascendis Pharma Bone Diseases AS a whollyowned subsidiary of Ascendis Pharma AS has entered into a million capped synthetic royalty funding
REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
Tuesday, September 03, 2024REGENXBIO Inc announced positive results from the Phase IIIIII CAMPSIITE trial of RGX for the treatment of patients with Mucopolysaccharidosis Type II MPS II also known as Hunter syndrome The results were presented at the Society for the Study of Inb...
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
Monday, September 02, 2024Belite Bio Inc a clinicalstage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs today announced
AFYREN Announces Signing of New Commercial Contract With US Nutraceutical Maker
Friday, August 30, 2024AFYREN a greentech company that offers manufacturers biobased lowcarbon ingredients produced using unique fermentation technology based on a completely circular model has signed a commercial contract with a US nutraceutical ingredients manufacturer
Merck Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)
Friday, August 30, 2024Merck a leading science and technology company today announced the first patient has been dosed in the Phase III MyClad trial NCT evaluating the efficacy and safety of oral cladribine for the treatment of generalized Myasthenia
Bayer and NextRNA Therapeutics Enter Strategic Collaboration to Develop Small Molecules Targeting Long Non-Coding RNAs (lncRNAs) in Oncology
Thursday, August 29, 2024Bayer and NextRNA Therapeutics a biotechnology company focused on developing transformative medicines to address long noncoding RNA lncRNAdriven diseases today announced that they have entered
Orchard Therapeutics Announces Multiple Presentations from across its Late-stage Neurometabolic Portfolio at SSIEM 2024
Thursday, August 29, 2024Orchard Therapeutics recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe today announced nine presentations from across its
